Table 2.

Current and recent trials of histone deacetylase inhibitors in prostate cancer.

Histone deacetylase inhibitor	Trial phase	Study design/results	ClinicalTrials.gov identifier
Vorinostat	Phase II	Trial of 400 mg daily PO vorinostat. Disease progression measured at 6 months. A total of 27 patients: 41% removed due to toxicity; 48% had disease progression; 7% did not progress.	NCT00330161
Vorinostat	Phase I	Trial of PO vorinostat and IV temsirolimus. Currently ongoing.	NCT01174199
Vorinostat	Phase II	Trial of PO vorinostat and PO bicalutamide with either IM leuprolide or SC goserelin acetate followed by radical prostatectomy. Currently ongoing.	NCT00589472
Romidepsin	Phase II	Trial of IV romidepsin. Disease progression measured at 6 months. A total of 35 patients: 31% removed due to toxicity; 6% filled RECIST criteria; 6% had more than 50% PSA decline.	NCT00106418
Pracinostat SB939	Phase II	Trial of PO pracinostat SB939. A total of 32 patients: 25% with PSA response; 6.3% with more than 50%; 22% with objectively stable disease at 1.6–8 months.	NCT01075308
Panobinostat	Phase I	Trial of IV panobinostat versus IV panobinostat, docetaxel, and prednisone. Disease progression measured at 6 months. A total of 16 patients, 8 in each arm. No apparent synergistic effect of combination.	NCT00663832
Panobinostat	Phase II	Trial of IV panobinostat. Disease progression measured at 24 weeks. A total of 35 patients: 14% had PSA decrease (none more than 50%).	NCT00667862
Panobinostat	Phase I/II	Trial of PO panobinostat with bicalutimide measured at 9 months. A total of 9 patients: 22% with more than 50% PSA reduction; 33% with stable PSA. Limited toxicity.	NCT00878436

IM, intramuscular; IV, intravenous; PO, by mouth; PSA, prostate-specific antigen; RECIST, response evaluation criteria in solid tumors; SC, subcutaneous.